Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The availability of effective, reliably accessible, and affordable treatments for snakebite envenoming is a critical and long unmet medical need. Recently, small, synthetic toxin-specific inhibitors with oral bioavailability used in conjunction with antivenom have been identified as having the potential to greatly improve outcomes after snakebite. Varespladib, a small, synthetic molecule that broadly and potently inhibits secreted phospholipase A2 (sPLA2s) venom toxins has renewed interest in this class of inhibitors due to its potential utility in the treatment of snakebite envenoming. The development of varespladib and its oral dosage form, varespladib-methyl, has been accelerated by previous clinical development campaigns to treat non-envenoming conditions related to ulcerative colitis, rheumatoid arthritis, asthma, sepsis, and acute coronary syndrome. To date, twenty-nine clinical studies evaluating the safety, pharmacokinetics (PK), and efficacy of varespladib for non-snakebite envenoming conditions have been completed in more than 4600 human subjects, and the drugs were generally well-tolerated and considered safe for use in humans. Since 2016, more than 30 publications describing the structure, function, and efficacy of varespladib have directly addressed its potential for the treatment of snakebite. This review summarizes preclinical findings and outlines the scientific support, the potential limitations, and the next steps in the development of varespladib’s use as a snakebite treatment, which is now in Phase 2 human clinical trials in the United States and India.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small molecule inhibitors currently lead the field of possible supplementary snake envenomation therapies, with phase II clinical trials ongoing for the PLA2 inhibitor varespladib (107) and the SVMP inhibitor DMPS ((108); ClinicalTrials.gov, 2021).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Snake Venom PLA 2 , a Promising Target for Broad-Spectrum Antivenom Drug Development
Xiao, H., Pan, H., Liao, K., Yang, M., & Huang, C. (2017) · BioMed Research International · doi:10.1155/2017/6592820 · Cited by 113
Gutiérrez, J. M., Lewin, M. R., Williams, D. J., & Lomonte, B. (2020) · Toxins · doi:10.3390/toxins12020131 · Cited by 92 · cited 1×
“…Venoms B. fasciatus, C.d. terrificus, N. scutatus, and O. scutellatus In vivo (mouse) acute toxicity/survival LY315920 ‡ and LY333013 10 mg/kg IV, PO Gutierréz et al., 2020 [78] 10 PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper…”
BackgroundSelf-citationSnake Antivenom: Challenges and Alternate Approaches
Alangode, A., Rajan, K., & Nair, B. G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114135 · Cited by 88 · cited 1×
“found that in blood samples obtained from healthy human volunteers, salts of the fatty acids arachidonic and oleic, and to a lesser extent, linoleic acid, enhanced fibrinogenolysis by Russell’s viper venom (RVV) proteinases [68,69].”
BackgroundXie, C., Albulescu, L.-O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J. (2020) · Biomedicines · doi:10.3390/biomedicines8060165 · Cited by 58 · cited 16×
“Recent observations have shown that the active pharmaceutical ingredient (API) varespladib (synonym LY315920) and its orally bioavailable methyl ester prodrug, varespladib-methyl (synonym LY333013), possess potent inhibitory activity against dozens of venom sPLA2s, with IC50 values ranging from picoto nanomolar concen…”
BackgroundInfluential
Research works printed but not linked: 88
- Calvete, 2017, Snakebite Envenoming, Nat. Rev. Dis. Primers, 3, 17063, 10.1038/nrdp.2017.63 · DOI · Paper page
- Longbottom, 2018, Vulnerability to Snakebite Envenoming: A Global Mapping of Hotspots, Lancet, 392, 673, 10.1016/S0140-6736(18)31224-8 · DOI · Paper page
- Vaiyapuri, S., Vaiyapuri, R., Ashokan, R., Ramasamy, K., Nattamaisundar, K., Jeyaraj, A., Chandran, V., Gajjeraman, P., Baksh, M.F., and Gibbins, J.M. (2013). Snakebite and Its Socio-Economic Impact on the Rural Population of Tamil Nadu, India. PLoS ONE, 8. · DOI · Paper page
- Williams, D.J., Faiz, M.A., Abela-Ridder, B., Ainsworth, S., Bulfone, T.C., Nickerson, A.D., Habib, A.G., Junghanss, T., Fan, H.W., and Turner, M. (2019). Strategy for a Globally Coordinated Response to a Priority Neglected Tropical Disease: Snakebite Envenoming. PLoS Negl. Trop. Dis., 13. · DOI · Paper page
- Harrison, R., and Gutiérrez, J. (2016). Priority Actions and Progress to Substantially and Sustainably Reduce the Mortality, Morbidity and Socioeconomic Burden of Tropical Snakebite. Toxins, 8. · DOI
- Mohapatra, B., Warrell, D.A., Suraweera, W., Bhatia, P., Dhingra, N., Jotkar, R.M., Rodriguez, P.S., Mishra, K., Whitaker, R., and Jha, P. (2011). Snakebite Mortality in India: A Nationally Representative Mortality Survey. PLoS Negl. Trop. Dis., 5. · DOI · Paper page
- Gerardo, 2019, Does This Patient Have a Severe Snake Envenomation?, JAMA Surg., 154, 346, 10.1001/jamasurg.2018.5069 · DOI
- Ozay, 2005, Clinical Characteristics of Children with Snakebite Poisioning and Management of Complications in the Pediatric Intensive Care Unit, Pediatr. Int., 47, 669, 10.1111/j.1442-200x.2005.02134.x · doi:10.1111/j.1442-200x.2005.02134.x
- Samprathi, 2020, Epidemiology and Outcomes of Early Morning Neuroparalytic Syndrome Following Snake Bite—A Retrospective Study, J. Trop. Pediatr., 66, 435, 10.1093/tropej/fmz084 · doi:10.1093/tropej/fmz084
- Karthika, 2021, Neurotoxic Snake Envenomation: Neostigmine-Induced Paradoxical Weakness, Indian J. Pediatr., 88, 406, 10.1007/s12098-020-03602-7 · doi:10.1007/s12098-020-03602-7
- Pach, 2021, Paediatric Snakebite Envenoming: Recognition and Management of Cases, Arch. Dis. Child, 106, 14, 10.1136/archdischild-2020-319428 · doi:10.1136/archdischild-2020-319428
- Suryanarayana, G., Rameshkumar, R., and Mahadevan, S. (2021). Retrospective Hospital-Based Cohort Study on Risk Factors of Poor Outcome in Pediatric Snake Envenomation. J. Trop. Pediatr., 67. · doi:10.1093/tropej/fmaa078
- Variawa, 2021, Prospective Review of Cytotoxic Snakebite Envenomation in a Paediatric Population, Toxicon, 190, 73, 10.1016/j.toxicon.2020.12.009 · doi:10.1016/j.toxicon.2020.12.009
- Tasoulis, T., and Isbister, G.K. (2017). A Review and Database of Snake Venom Proteomes. Toxins, 9. · DOI · Paper page
- Pach, 2020, Paediatric Snakebite Envenoming: The World’s Most Neglected “Neglected Tropical Disease”?, Arch. Dis. Child, 105, 1135, 10.1136/archdischild-2020-319417 · doi:10.1136/archdischild-2020-319417
- Rucavado, 2018, Unresolved Issues in the Understanding of the Pathogenesis of Local Tissue Damage Induced by Snake Venoms, Toxicon, 148, 123, 10.1016/j.toxicon.2018.04.016 · DOI
- Montecucco, 2008, Cellular Pathology Induced by Snake Venom Phospholipase A 2 Myotoxins and Neurotoxins: Common Aspects of Their Mechanisms of Action, Cell. Mol. Life Sci., 65, 2897, 10.1007/s00018-008-8113-3 · DOI · Paper page
- Lomonte, 2012, Snake Venom Lys49 Myotoxins: From Phospholipases A2 to Non-Enzymatic Membrane Disruptors, Toxicon, 60, 520, 10.1016/j.toxicon.2012.02.007 · DOI · Paper page
- Lomonte, 2013, Phospholipases A2: Unveiling the Secrets of a Functionally Versatile Group of Snake Venom Toxins, Toxicon, 62, 27, 10.1016/j.toxicon.2012.09.006 · DOI · Paper page
- Mora, J., Mora, R., Lomonte, B., and Gutiérrez, J.M. (2008). Effects of Bothrops Asper Snake Venom on Lymphatic Vessels: Insights into a Hidden Aspect of Envenomation. PLoS Negl. Trop. Dis., 2. · DOI · Paper page
- Lewin, 2019, Neutralizing Properties of LY315920 toward Snake Venom Group I and II Myotoxic Phospholipases A2, Toxicon, 157, 1, 10.1016/j.toxicon.2018.11.292 · DOI · Paper page
- Salvador, 2021, The Synthetic Varespladib Molecule Is a Multi-Functional Inhibitor for PLA2 and PLA2-like Ophidic Toxins, Biochim. Et Biophys. Acta (BBA) Gen. Subj., 1865, 129913, 10.1016/j.bbagen.2021.129913 · DOI
- Salvador, 2019, Structural Basis for Phospholipase A2-like Toxin Inhibition by the Synthetic Compound Varespladib (LY315920), Sci. Rep., 9, 17203, 10.1038/s41598-019-53755-5 · DOI · Paper page
- Clare, 2021, Small Molecule Drug Discovery for Neglected Tropical Snakebite, Trends Pharmacol. Sci., 42, 340, 10.1016/j.tips.2021.02.005 · DOI · Paper page
- Laustsen, 2016, From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy, Curr. Pharm. Des., 22, 5270, 10.2174/1381612822666160623073438 · DOI · Paper page
- Bulfone, 2018, Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite, J. Trop. Med., 2018, 1, 10.1155/2018/4320175 · DOI · Paper page
- Williams, H.F., Mellows, B.A., Mitchell, R., Sfyri, P., Layfield, H.J., Salamah, M., Vaiyapuri, R., Collins-Hooper, H., Bicknell, A.B., and Matsakas, A. (2019). Mechanisms Underpinning the Permanent Muscle Damage Induced by Snake Venom Metalloprotease. PLoS Negl. Trop. Dis., 13. · DOI
- Prasarnpun, 2005, Envenoming Bites by Kraits: The Biological Basis of Treatment-Resistant Neuromuscular Paralysis, Brain, 128, 2987, 10.1093/brain/awh642 · DOI
- Senji Laxme, R.R., Khochare, S., de Souza, H.F., Ahuja, B., Suranse, V., Martin, G., Whitaker, R., and Sunagar, K. (2019). Beyond the ‘Big Four’: Venom Profiling of the Medically Important yet Neglected Indian Snakes Reveals Disturbing Antivenom Deficiencies. PLoS Negl. Trop. Dis., 13. · DOI · Paper page
- Abraham, 2003, Efficacy and Safety of LY315920Na/S-5920, a Selective Inhibitor of 14-KDa Group IIA Secretory Phospholipase A2, in Patients with Suspected Sepsis and Organ Failure, Crit. Care Med., 31, 718, 10.1097/01.CCM.0000053648.42884.89 · DOI
- Dennis, 2011, Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention, Chem. Rev., 111, 6130, 10.1021/cr200085w · DOI · Paper page
- Bickler, P.E. (2020). Amplification of Snake Venom Toxicity by Endogenous Signaling Pathways. Toxins, 12. · DOI
- Ranawaka, U.K., Lalloo, D.G., and de Silva, H.J. (2013). Neurotoxicity in Snakebite—The Limits of Our Knowledge. PLoS Negl. Trop. Dis., 7. · DOI · Paper page
- Quartino, 2018, Intravascular Hemolysis Induced by Phospholipases A 2 from the Venom of the Eastern Coral Snake, Micrurus Fulvius: Functional Profiles of Hemolytic and Non-Hemolytic Isoforms, Toxicol. Lett., 286, 39, 10.1016/j.toxlet.2017.11.037 · DOI
- Berling, 2015, Hematologic Effects and Complications of Snake Envenoming, Transfus. Med. Rev., 29, 82, 10.1016/j.tmrv.2014.09.005 · DOI · Paper page
- Noutsos, 2019, Snakebite Associated Thrombotic Microangiopathy: A Protocol for the Systematic Review of Clinical Features, Outcomes, and Role of Interventions, Syst. Rev., 8, 212, 10.1186/s13643-019-1133-2 · DOI
- Sitprija, 2008, Animal Toxins and the Kidney, Nat. Clin. Pract. Nephrol., 4, 616, 10.1038/ncpneph0941 · DOI
- Gopalakrishnan, 2019, Snake Envenoming─An Underreported Cause of Acute Kidney Injury, Kidney Int. Rep., 4, 643, 10.1016/j.ekir.2019.03.014 · doi:10.1016/j.ekir.2019.03.014
- Alfred, 2019, Acute Kidney Injury Following Eastern Russell’s Viper (Daboia siamensis) Snakebite in Myanmar, Kidney Int. Rep., 4, 1337, 10.1016/j.ekir.2019.05.017 · doi:10.1016/j.ekir.2019.05.017
- Krishnamurthy, 2015, Russell’s Viper Envenomation-Associated Acute Kidney Injury in Children in Southern India, Indian Pediatr., 52, 583, 10.1007/s13312-015-0679-x · doi:10.1007/s13312-015-0679-x
- Kumar, 2022, Snake Envenomation-Induced Acute Kidney Injury: Prognosis and Long-Term Renal Outcomes, Postgrad Med. J., 98, 264, 10.1136/postgradmedj-2020-139021 · DOI
- Harshavardhan, 2013, A Study on the Acute Kidney Injury in Snake Bite Victims in a Tertiary Care Centre, J. Clin. Diagn. Res., 7, 853
- Villalta, 2019, Nephrotoxicity Induced by the Venom of Hypnale Hypnale from Sri Lanka: Studies on Isolated Perfused Rat Kidney and Renal Tubular Cell Lines, Toxicon, 165, 40, 10.1016/j.toxicon.2019.04.014 · DOI
- Vuong, N.T., Jackson, T.N.W., and Wright, C.E. (2021). Role of Phospholipases A2 in Vascular Relaxation and Sympatholytic Effects of Five Australian Brown Snake, Pseudonaja spp., Venoms in Rat Isolated Tissues. Front. Pharmacol., 12. · DOI
- Arroyo, 1986, Pathogenesis of Myonecrosis Induced by Coral Snake (Micrurus nigrocinctus) Venom in Mice, Br. J. Exp. Pathol., 67, 1
- Xiao, H., Li, H., Zhang, D., Li, Y., Sun, S., Huang, C., Xiao, H., Li, H., Zhang, D., and Li, Y. (2018). Inactivation of Venom PLA2 Alleviates Myonecrosis and Facilitates Muscle Regeneration in Envenomed Mice: A Time Course Observation. Molecules, 23. · DOI
- Neale, 2018, Spine-Bellied Sea Snake (Hydrophis curtus) Venom Shows Greater Skeletal Myotoxicity Compared with Cardiac Myotoxicity, Toxicon, 143, 108, 10.1016/j.toxicon.2018.01.009 · doi:10.1016/j.toxicon.2018.01.009
- Lago, 2012, Myotoxicity and Nephrotoxicity by Micrurus Venoms in Experimental Envenomation, Toxicon, 59, 356, 10.1016/j.toxicon.2011.11.009 · DOI
- Ownby, 2003, Skeletal Muscle Degeneration Induced by Venom Phospholipases A2: Insights into the Mechanisms of Local and Systemic Myotoxicity, Toxicon, 42, 915, 10.1016/j.toxicon.2003.11.005 · DOI · Paper page
- Johnston, 2013, Mulga Snake (Pseudechis australis) Envenoming: A Spectrum of Myotoxicity, Anticoagulant Coagulopathy, Haemolysis and the Role of Early Antivenom Therapy—Australian Snakebite Project (ASP-19), Clin. Toxicol. (Phila), 51, 417, 10.3109/15563650.2013.787535 · doi:10.3109/15563650.2013.787535
- Burnouf, 2014, A Multicomponent Strategy to Improve the Availability of Antivenom for Treating Snakebite Envenoming, Bull. World Health Organ., 92, 526, 10.2471/BLT.13.132431 · DOI
- (2019). Williams; Layfield; Vallance; Patel; Bicknell; Trim; Vaiyapuri The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites. Toxins, 11. · DOI
- Lewin, M., Samuel, S., Merkel, J., and Bickler, P. (2016). Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins, 8. · DOI · Paper page
- (2011). Adis R&D Profile Varespladib. Adis R&D Insight, 11, 137–143. · DOI · Paper page
- Wery, 1991, Structure of Recombinant Human Rheumatoid Arthritic Synovial Fluid Phospholipase A2 at 2.2 A Resolution, Nature, 352, 79, 10.1038/352079a0 · doi:10.1038/352079a0
- Rosenson, 2010, Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients, J. Am. Coll. Cardiol., 56, 1079, 10.1016/j.jacc.2010.06.015 · DOI
- Nicholls, 2012, Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial, Cardiovasc. Drugs Ther., 26, 71, 10.1007/s10557-011-6358-9 · DOI
- Santoso, 2020, Phospholipase A2 Is an Inflammatory Predictor in Cardiovascular Diseases: Is There Any Spacious Room to Prove the Causation?, Curr. Cardiol. Rev., 16, 3, 10.2174/1573403X15666190531111932 · DOI
- 2014, Acute Coronary Syndromes: Targeting Inflammation-What Has the VISTA-16 Trial Taught Us?, Nat. Rev. Cardiol., 11, 130, 10.1038/nrcardio.2013.220 · DOI
- Nicholls, 2014, Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome, JAMA, 311, 252, 10.1001/jama.2013.282836 · DOI · Paper page
- Wang, Y., Zhang, J., Zhang, D., Xiao, H., Xiong, S., and Huang, C. (2018). Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules, 23. · DOI · Paper page
- Lewin, M.R.M.R.M.R., Gutiérrez, J.M., Samuel, S.P.S.P.S.P., Herrera, M., Bryan-Quirós, W., Lomonte, B., Bickler, P.E.P.E.P.E., Bulfone, T.C.T.C., Williams, D.J.D.J.D.J., and María Gutiérrez, J. (2018). Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus Scutellatus) Venom. Toxins, 10. · DOI · Paper page
- Lewin, M.R.M.R., Gilliam, L.L.L., Gilliam, J., Samuel, S.P.S.P., Bulfone, T.C.T.C., Bickler, P.E.P.E., and Gutiérrez, J.M.J.M. (2018). Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of Micrurus Fulvius (Eastern Coral Snake) Venom. Toxins, 10. · DOI · Paper page
- Bittenbinder, M.A., Zdenek, C.N., op den Brouw, B., Youngman, N.J., Dobson, J.S., Naude, A., Vonk, F.J., and Fry, B.G. (2018). Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib). Toxins, 10. · DOI · Paper page
- Zdenek, 2019, Clinical Implications of Convergent Procoagulant Toxicity and Differential Antivenom Efficacy in Australian Elapid Snake Venoms, Toxicol. Lett., 316, 171, 10.1016/j.toxlet.2019.08.014 · DOI
- Zdenek, 2020, Anticoagulant Activity of Black Snake (Elapidae: Pseudechis) Venoms: Mechanisms, Potency, and Antivenom Efficacy, Toxicol. Lett., 330, 176, 10.1016/j.toxlet.2020.05.014 · DOI
- Alangode, 2020, Sodium Oleate, Arachidonate, and Linoleate Enhance Fibrinogenolysis by Russell’s Viper Venom Proteinases and Inhibit FXIIIa; a Role for Phospholipase A2 in Venom Induced Consumption Coagulopathy, Toxicon, 186, 83, 10.1016/j.toxicon.2020.07.011 · DOI
- Xie, C., Albulescu, L.-O.O., Bittenbinder, M.A., Somsen, G.W., Vonk, F.J., Casewell, N.R., and Kool, J. (2020). Neutralizing Effects of Small Molecule Inhibitors and Metal Chelators on Coagulopathic Viperinae Snake Venom Toxins. Biomedicines, 8. · doi:10.1101/2020.06.02.129643
- Xie, 2021, Erythrocyte Haemotoxicity Profiling of Snake Venom Toxins after Nanofractionation, J. Chromatogr. B, 1176, 122586, 10.1016/j.jchromb.2021.122586 · DOI
- Kazandjian, T.D., Arrahman, A., Still, K.B.M., Somsen, G.W., Vonk, F.J., Casewell, N.R., Wilkinson, M.C., and Kool, J. (2021). Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib. Toxins, 13. · DOI
- Barbosa, 2021, Quantum Biochemical Investigation of Lys49-PLA2 from Bothrops moojeni, J. Phys. Chem. B, 125, 12972, 10.1021/acs.jpcb.1c07298 · doi:10.1021/acs.jpcb.1c07298
- Ownby, 1999, Lysine 49 Phospholipase A2 Proteins, Toxicon, 37, 411, 10.1016/S0041-0101(98)00188-3 · DOI · Paper page
- White, 1996, Sequence Analysis of Lys49 Phospholipase A2 Myotoxins: A Highly Conserved Class of Proteins, Toxicon, 34, 1237, 10.1016/S0041-0101(96)00111-0 · doi:10.1016/s0041-0101(96)00111-0
- Chacur, 2004, Snake Venom Phospholipase A2s (Asp49 and Lys49) Induce Mechanical Allodynia upon Peri-Sciatic Administration: Involvement of Spinal Cord Glia, Proinflammatory Cytokines and Nitric Oxide, Pain, 108, 180, 10.1016/j.pain.2003.12.023 · DOI
- Gaspar, 2022, In Vivo Treatment with Varespladib, a Phospholipase A2 Inhibitor, Prevents the Peripheral Neurotoxicity and Systemic Disorders Induced by Micrurus Corallinus (Coral Snake) Venom in Rats, Toxicol. Lett., 356, 54, 10.1016/j.toxlet.2021.11.003 · DOI
- Gaspar, 2022, Partial Efficacy of a Brazilian Coralsnake Antivenom and Varespladib in Neutralizing Distinct Toxic Effects Induced by Sublethal Micrurus Dumerilii Carinicauda Envenoming in Rats, Toxicon, 213, 99, 10.1016/j.toxicon.2022.04.014 · DOI
- Tan, 2022, Varespladib (LY315920) Rescued Mice from Fatal Neurotoxicity Caused by Venoms of Five Major Asiatic Kraits (Bungarus Spp.) in an Experimental Envenoming and Rescue Model, Acta Trop., 227, 106289, 10.1016/j.actatropica.2021.106289 · DOI
- Lewin, 2020, Varespladib (LY315920) Inhibits Neuromuscular Blockade Induced by Oxyuranus Scutellatus Venom in a Nerve-Muscle Preparation, Toxicon, 187, 101, 10.1016/j.toxicon.2020.08.023 · DOI
- Maciel, 2021, Varespladib (LY315920) Prevents Neuromuscular Blockage and Myotoxicity Induced by Crotoxin on Mouse Neuromuscular Preparations, Toxicon, 202, 40, 10.1016/j.toxicon.2021.09.009 · DOI
- Oliveira, 2022, Effect of the Phospholipase A2 Inhibitor Varespladib, and Its Synergism with Crotalic Antivenom, on the Neuromuscular Blockade Induced by Crotalus Durissus Terrificus Venom (with and without Crotamine) in Mouse Neuromuscular Preparations, Toxicon, 214, 54, 10.1016/j.toxicon.2022.05.001 · DOI
- Zinenko, O., Tovstukha, I., and Korniyenko, Y. (2020). PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper Vipera Berus Nikolskii. Toxins, 12. · DOI
- Liu, 2021, Snake Venom Proteome of Protobothrops Mucrosquamatus in Taiwan: Delaying Venom-Induced Lethality in a Rodent Model by Inhibition of Phospholipase A2 Activity with Varespladib, J Proteomics, 234, 104084, 10.1016/j.jprot.2020.104084 · DOI
- Gutierres, P.G., Pereira, D.R., Vieira, N.L., Arantes, L.F., Silva, N.J., Torres-Bonilla, K.A., Hyslop, S., Morais-Zani, K., Nogueira, R.M.B., and Rowan, E.G. (2022). Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis Muta Rhombeata (South-American Bushmaster) Venom. Front. Pharmacol., 12. · DOI
- Albulescu, 2020, A Therapeutic Combination of Two Small Molecule Toxin Inhibitors Provides Broad Preclinical Efficacy against Viper Snakebite, Nat. Commun., 11, 6094, 10.1038/s41467-020-19981-6 · DOI · Paper page
- Youngman, 2020, Varespladib (LY315920) Neutralises Phospholipase A2 Mediated Prothrombinase-Inhibition Induced by Bitis Snake Venoms, Comp. Biochem. Physiol. Part C Toxicol. Pharmacol., 236, 108818, 10.1016/j.cbpc.2020.108818 · DOI
- Dashevsky, 2021, Anticoagulant Micrurus Venoms: Targets and Neutralization, Toxicol. Lett., 337, 91, 10.1016/j.toxlet.2020.11.010 · DOI
- Lomonte, 2014, Intravascular Hemolysis Induced by the Venom of the Eastern Coral Snake, Micrurus Fulvius, in a Mouse Model: Identification of Directly Hemolytic Phospholipases A2, Toxicon, 90, 26, 10.1016/j.toxicon.2014.07.010 · DOI
- Arrahman, A., Kazandjian, T.D., Still, K.B.M., Slagboom, J., Somsen, G.W., Vonk, F.J., Casewell, N.R., and Kool, J. (2022). A Combined Bioassay and Nanofractionation Approach to Investigate the Anticoagulant Toxins of Mamba and Cobra Venoms and Their Inhibition by Varespladib. Toxins, 14. · DOI
Cited by
Carter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., et al. (2022) · Toxins · doi:10.3390/toxins15010022 · Cited by 39
“Extensive preclinical data support the hypothesis that varespladib is a broad-spectrum, DTI of sPLA2 that could help overcome some of the limitations of conventional antivenom [34].”
BackgroundSelf-citationLiu, J., Wang, L., Xie, M., Zhao, W., Sun, J., Jin, Y., Liu, M., Zhao, J., Cheng, L., Wen, C., et al. (2025) · Redox Report · doi:10.1080/13510002.2025.2507557 · Cited by 13
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Lewin, M. R., Carter, R. W., Matteo, I. A., Samuel, S. P., Rao, S., Fry, B. G., & Bickler, P. E.
- Affiliations
- Division of Research, Ophirex, Inc., Corte Madera, CA 94925, USA
- Center for Exploration and Travel Health, California Academy of Sciences, San Francisco, CA 94118, USA
- Venom Evolution Lab, School of Biological Science, University of Queensland, St. Lucia, QLD 4072, Australia
- Venue
- Toxins
- Publisher
- MDPI AG
- Published
- 2022-11-11
- Volume
- 14
- Issue
- 11
- Pages
- 783
- ISSN
- 2072-6651
- Cited by
- 98
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. https://app.cochat.ai/papers/10.3390/toxins14110783
- The paper
- Lewin, M. R., Carter, R. W., Matteo, I. A., Samuel, S. P., Rao, S., Fry, B. G., & Bickler, P. E. (2022). Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins. https://doi.org/10.3390/toxins14110783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.